drugset / Trial / NCT05222269

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

NCT05222269

Phase 2 Terminated 1 enrolled Pentixapharm AG
NaSingle-groupOpen-labelDiagnostic

Summary

This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of \[68Ga\]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.

Timeline

Start
2022-10-05
Primary completion
2023-01-25
Completion
2023-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-Pentixafor Peptide 150 mbq Intravenous